CAIX/XII-IN-16

CAIX/XII-IN-16 (Compound 5d) is a selective inhibitor of CA IX/XII and c-Met. CAIX/XII-IN-16‘s Ki values for hCA IX, hCA XII and CA I are 10.6, 31.8 and 2361 nM respectively, and its IC50 value for c-Met is 0.49 μM. CAIX/XII-IN-16 exhibits significantly enhanced cytotoxicity against colon cancer cells under hypoxic conditions. CAIX/XII-IN-16 causes cell cycle arrest and induces apoptosis (apoptosis) . CAIX/XII-IN-16 significantly enhances the efficacy of Oxaliplatin (HY-17371) and 5-Fluorouracil (HY-90006) . CAIX/XII-IN-16 can be used for studies on chemotherapy resistance related to hypoxia[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Carbonic Anhydrase; c-Met/HGFR

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

CC1=CC=CC2=C1NC(/C2=N\NC(C3=C(N(N=N3)C4=CC=C(C=C4)S(N)(=O)=O)C)=O)=O

Molecular Formula

C19H17N7O4S

Molecular Weight

439.45

References & Citations

[1]Eldehna WM, et al. Identification of isatin-triazole-benzenesulfonamide hybrids as dual hCA IX/XII and c-met inhibitors with hypoxia-mediated chemo-sensitizing activity. Bioorg Chem. 2025 Oct 6;166:109071.